China Pharma Holdings, Inc. received SFDA approval for a generic version of Bumetanide injection, a diuretic that is given for a wide variety of indications. The company said the approval shows the SFDA has now adjusted to the new drug approval regulations implemented on October 1, 2007, and is, once again, completing new drug applications. The Bumetanide ruling bodes well for other drugs that China Pharma has submitted for approval. The company's income statement is strong, but its balance sheet has some issues. More details...

Stock Symbol: (OTCBB: CPHI)